Literature DB >> 23677707

Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enema.

Carolina Gracia-Iguacel1, Emilio Gonzalez-Parra, Laura Rodriguez-Osorio, Ana Belén Sanz, Yolanda Almaden, Concepcion de la Piedra, Jesus Egido, Mariano Rodriguez, Alberto Ortiz.   

Abstract

Both parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) are phosphaturic hormones. These hormones should increase in response to phosphate excess. However, they also regulate serum calcium; PTH increases serum calcium concentration and FGF23 suppresses renal production of calcitriol, favoring hypocalcemia. We report the case of an 83-year-old woman with hyperphosphatemia and hypocalcemia resulting from phosphate-containing enemas. PTH and calcitriol increased in response to hypocalcemia, and FGF23 increased in response to hyperphosphatemia. Unexpectedly, peak FGF23 did not coincide with peak serum phosphate. Rather, peak FG23 was observed only after severe hypocalcemia was partially corrected with exogenous calcium administration, even though serum phosphate had been already decreasing for 32 h. Correction of severe hypocalcemia was thus associated with peak FGF23 values and with a precipitous decrease in PTH. Peak FGF23 was followed by an accelerated decrease in serum phosphate and significant phosphaturia. This clinical report is consistent with experimental data in rats showing a blunted FGF23 response to high phosphate in the presence of severe hypocalcemia. Thus, complementary experimental and clinical data suggest that partial correction of severe hypocalcemia is required for optimal FGF23-mediated phosphaturia, which takes place despite correction of PTH levels. We believe this the first human report suggesting blunting of the FGF23 response to high phosphate by severe hypocalcemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23677707     DOI: 10.1007/s00774-013-0435-z

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  21 in total

Review 1.  FGF23 and PTH--double agents at the heart of CKD.

Authors:  Justin Silver; Mariano Rodriguez; Eduardo Slatopolsky
Journal:  Nephrol Dial Transplant       Date:  2012-03-23       Impact factor: 5.992

2.  Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.

Authors:  Marc G Vervloet; Frans J van Ittersum; Rahel M Büttler; Annemieke C Heijboer; Marinus A Blankenstein; Piet M ter Wee
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 8.237

3.  Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

Authors:  Serge L Ferrari; Jean-Philippe Bonjour; René Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

Review 4.  Phosphate: a stealthier killer than previously thought?

Authors:  Emilio Gonzalez-Parra; Jose Tuñón; Jesus Egido; Alberto Ortiz
Journal:  Cardiovasc Pathol       Date:  2012-03-16       Impact factor: 2.185

5.  Intermediate bioelectrolyte changes after phospho-soda or polyethylene glycol precolonoscopic laxatives in a population undergoing health examinations.

Authors:  Wei-Chih Kan; Hsien-Yi Wang; Chih-Chiang Chien; Che-Kim Tan; Ching-Yih Lin; Shih-Bin Su
Journal:  Nephrol Dial Transplant       Date:  2011-05-26       Impact factor: 5.992

6.  Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men.

Authors:  Y Nishida; Y Taketani; H Yamanaka-Okumura; F Imamura; A Taniguchi; T Sato; E Shuto; K Nashiki; H Arai; H Yamamoto; E Takeda
Journal:  Kidney Int       Date:  2006-10-25       Impact factor: 10.612

Review 7.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

8.  Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience.

Authors:  Yaacov Ori; Benaya Rozen-Zvi; Avry Chagnac; Michal Herman; Boris Zingerman; Eli Atar; Uzi Gafter; Asher Korzets
Journal:  Arch Intern Med       Date:  2012-02-13

9.  Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.

Authors:  Hitoshi Saito; Akira Maeda; Shu-Ichi Ohtomo; Michinori Hirata; Kenichiro Kusano; Shigeaki Kato; Etsuro Ogata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2004-11-05       Impact factor: 5.157

10.  Calcium deficiency reduces circulating levels of FGF23.

Authors:  María E Rodriguez-Ortiz; Ignacio Lopez; Juan R Muñoz-Castañeda; Julio M Martinez-Moreno; Alan Peralta Ramírez; Carmen Pineda; Antonio Canalejo; Philippe Jaeger; Escolastico Aguilera-Tejero; Mariano Rodriguez; Arnold Felsenfeld; Yolanda Almaden
Journal:  J Am Soc Nephrol       Date:  2012-05-10       Impact factor: 10.121

View more
  3 in total

Review 1.  Next-generation phosphate binders: focus on iron-based binders.

Authors:  Dimitra Nastou; Beatriz Fernández-Fernández; Usama Elewa; Liliana González-Espinoza; Emilio González-Parra; Maria D Sanchez-Niño; Alberto Ortiz
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

2.  Evaluation of intestinal phosphate binding to improve the safety profile of oral sodium phosphate bowel cleansing.

Authors:  Stef Robijn; Benjamin A Vervaet; Patrick C D'Haese; Anja Verhulst
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

3.  Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients.

Authors:  Forough Saki; Seyed Reza Kassaee; Azita Salehifar; Gholam Hossein Ranjbar Omrani
Journal:  BMC Nephrol       Date:  2020-05-12       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.